Search Results

postmenopausal women, except that tamoxifen is the preferred adjuvant treatment. 5 – 9 There are limited clinical data on the efficacy of single-agent aromatase inhibitors in men, and aromatase inhibitors may be combined with gonadotropic hormone

lumpectomy and tamoxifen with or without radiation. The radiation group was significantly less likely to experience local relapse at 5 years (0.6% vs 7.7%; P <.001) and axillary relapse (0.5% vs 2.5%; P =.049). However, no difference was seen in distant

. From pharmacy records, we measured nonadherence (filled prescriptions covered ≤80% of potential time on therapy), nonpersistence (continuous period >6 months when no prescription was filled), and frequency and timing of planned switches from tamoxifen

an opposed tangent technique, which delivered 50.4 Gy in 28 fractions to the whole breast, followed by a 10-Gy boost to the lumpectomy cavity. She was then lost to follow-up and did not receive the intended course of adjuvant tamoxifen nor the

-term use of hormonal agents such as tamoxifen and aromatase inhibitors can cause vasomotor and musculoskeletal symptoms. 3 For both men and women who have had surgery for rectal cancer, sexual problems afterward are “common, multifactorial, inadequately

endocrine therapy with goserelin and tamoxifen. This regimen was continued for 2 years until the patient experienced relapse with multiple lung metastases. She received various therapies over the next 4.5 years, including chemotherapy, endocrine therapy

-CSF) with each cycle and the lack of safety data on G-CSF in pregnancy. Tamoxifen and trastuzumab are contraindicated in pregnancy because of the high frequency of congenital abnormalities and poor fetal outcomes. 15 , 17 – 19 Radiation therapy may be a

cancer. 10 If the rate of unrelated cancers in the opposite breast is the same as those in the same breast, then approximately half of the ipsilateral recurrences could be biologically new cancers. The greater effectiveness of radiation, tamoxifen, and

trastuzumab: a clinically active regimen [abstract] . J Clin Oncol 2005 ; 23 ( suppl 1 ): Abstract 559 . 68. Chu I Blackwell K Chen S . The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell

the risk of death compared with standard chemotherapy, 27 and overtreatment with lumpectomy plus tamoxifen and radiation therapy has shown no benefit compared with lumpectomy plus adjuvant therapy with tamoxifen alone. 28 In our study of patients